Molecular Biophysics Unit, Indian Institute of Science, Bangalore - 560 012, India.
J Struct Biol. 2011 Nov;176(2):238-49. doi: 10.1016/j.jsb.2011.07.018. Epub 2011 Aug 6.
The β-hydroxyacyl-acyl carrier protein dehydratase of Plasmodium falciparum (PfFabZ) catalyzes the third and important reaction of the fatty acid elongation cycle. The crystal structure of PfFabZ is available in hexameric (active) and dimeric (inactive) forms. However, PfFabZ has not been crystallized with any bound inhibitors until now. We have designed a new condition to crystallize PfFabZ with its inhibitors bound in the active site, and determined the crystal structures of four of these complexes. This is the first report on any FabZ enzyme with active site inhibitors that interact directly with the catalytic residues. Inhibitor binding not only stabilized the substrate binding loop but also revealed that the substrate binding tunnel has an overall shape of "U". In the crystal structures, residue Phe169 located in the middle of the tunnel was found to be in two different conformations, open and closed. Thus, Phe169, merely by changing its side chain conformation, appears to be controlling the length of the tunnel to make it suitable for accommodating longer substrates. The volume of the substrate binding tunnel is determined by the sequence as well as by the conformation of the substrate binding loop region and varies between organisms for accommodating fatty acids of different chain lengths. This report on the crystal structures of the complexes of PfFabZ provides the structural basis of the inhibitory mechanism of the enzyme that could be used to improve the potency of inhibitors against an important component of fatty acid synthesis common to many infectious organisms.
疟原虫(Plasmodium falciparum)的β-羟酰基辅酶 A 脱水酶(PfFabZ)催化脂肪酸延长循环的第三个也是重要的反应。PfFabZ 的晶体结构以六聚体(活性)和二聚体(非活性)两种形式存在。然而,迄今为止,PfFabZ 还没有与任何结合的抑制剂一起结晶。我们设计了一种新的条件来结晶 PfFabZ,使其与结合在活性部位的抑制剂结合,并确定了其中四个复合物的晶体结构。这是第一个关于任何具有与催化残基直接相互作用的活性部位抑制剂的 FabZ 酶的报告。抑制剂结合不仅稳定了底物结合环,还揭示了底物结合隧道具有“U”形的整体形状。在晶体结构中,位于隧道中间的残基 Phe169 被发现处于两种不同的构象,即开放和关闭。因此,Phe169 仅仅通过改变其侧链构象,似乎在控制隧道的长度,使其适合容纳更长的底物。底物结合隧道的体积由序列以及底物结合环区域的构象决定,并且在不同的生物体之间变化,以适应不同链长的脂肪酸。本报告关于 PfFabZ 复合物的晶体结构为该酶的抑制机制提供了结构基础,这可能有助于提高抑制剂对许多感染性生物体中共同的脂肪酸合成重要成分的效力。